nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP1A1—Clobetasol propionate—psoriasis	0.0867	0.125	CbGbCtD
Fluvoxamine—CYP1A1—Methoxsalen—psoriasis	0.0456	0.0659	CbGbCtD
Fluvoxamine—CYP3A5—Beclomethasone—psoriasis	0.0394	0.0571	CbGbCtD
Fluvoxamine—CYP1A2—Clobetasol propionate—psoriasis	0.0387	0.056	CbGbCtD
Fluvoxamine—CYP1A1—Cholecalciferol—psoriasis	0.0302	0.0436	CbGbCtD
Fluvoxamine—CYP2B6—Cholecalciferol—psoriasis	0.023	0.0333	CbGbCtD
Fluvoxamine—CYP1A2—Methoxsalen—psoriasis	0.0203	0.0294	CbGbCtD
Fluvoxamine—CYP2D6—Hydroxyurea—psoriasis	0.0183	0.0265	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0168	0.0243	CbGbCtD
Fluvoxamine—CYP3A7—Hydrocortisone—psoriasis	0.0168	0.0243	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0159	0.0229	CbGbCtD
Fluvoxamine—CYP3A7—Cyclosporine—psoriasis	0.0159	0.0229	CbGbCtD
Fluvoxamine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0157	0.0227	CbGbCtD
Fluvoxamine—CYP2C19—Cholecalciferol—psoriasis	0.0146	0.0211	CbGbCtD
Fluvoxamine—CYP3A4—Calcitriol—psoriasis	0.0137	0.0198	CbGbCtD
Fluvoxamine—CYP1A1—Dexamethasone—psoriasis	0.0131	0.0189	CbGbCtD
Fluvoxamine—CYP3A5—Hydrocortisone—psoriasis	0.0126	0.0182	CbGbCtD
Fluvoxamine—CYP2C9—Cholecalciferol—psoriasis	0.0121	0.0176	CbGbCtD
Fluvoxamine—CYP3A5—Cyclosporine—psoriasis	0.0119	0.0172	CbGbCtD
Fluvoxamine—CYP2D6—Cholecalciferol—psoriasis	0.0111	0.0161	CbGbCtD
Fluvoxamine—CYP3A4—Methoxsalen—psoriasis	0.0107	0.0154	CbGbCtD
Fluvoxamine—CYP3A7—Dexamethasone—psoriasis	0.0104	0.0151	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0104	0.0151	CbGbCtD
Fluvoxamine—ABCB1—Mycophenolate mofetil—psoriasis	0.0102	0.0148	CbGbCtD
Fluvoxamine—CYP2C19—Prednisone—psoriasis	0.0101	0.0146	CbGbCtD
Fluvoxamine—CYP2E1—Dexamethasone—psoriasis	0.0101	0.0146	CbGbCtD
Fluvoxamine—CYP2B6—Dexamethasone—psoriasis	0.00995	0.0144	CbGbCtD
Fluvoxamine—CYP2C19—Cyclosporine—psoriasis	0.0096	0.0139	CbGbCtD
Fluvoxamine—ABCB1—Betamethasone—psoriasis	0.00877	0.0127	CbGbCtD
Fluvoxamine—ABCB1—Prednisolone—psoriasis	0.00865	0.0125	CbGbCtD
Fluvoxamine—ABCB1—Hydrocortisone—psoriasis	0.0082	0.0119	CbGbCtD
Fluvoxamine—ABCB1—Prednisone—psoriasis	0.00817	0.0118	CbGbCtD
Fluvoxamine—CYP2C9—Cyclosporine—psoriasis	0.00798	0.0115	CbGbCtD
Fluvoxamine—CYP3A5—Dexamethasone—psoriasis	0.00784	0.0113	CbGbCtD
Fluvoxamine—ABCB1—Cyclosporine—psoriasis	0.00775	0.0112	CbGbCtD
Fluvoxamine—CYP2D6—Cyclosporine—psoriasis	0.0073	0.0106	CbGbCtD
Fluvoxamine—CYP3A4—Cholecalciferol—psoriasis	0.00706	0.0102	CbGbCtD
Fluvoxamine—CYP2C19—Dexamethasone—psoriasis	0.00632	0.00914	CbGbCtD
Fluvoxamine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00612	0.00886	CbGbCtD
Fluvoxamine—CYP3A4—Triamcinolone—psoriasis	0.00612	0.00886	CbGbCtD
Fluvoxamine—CYP2C9—Dexamethasone—psoriasis	0.00526	0.0076	CbGbCtD
Fluvoxamine—CYP3A4—Betamethasone—psoriasis	0.00525	0.0076	CbGbCtD
Fluvoxamine—CYP3A4—Prednisolone—psoriasis	0.00518	0.0075	CbGbCtD
Fluvoxamine—ABCB1—Dexamethasone—psoriasis	0.0051	0.00738	CbGbCtD
Fluvoxamine—CYP3A4—Hydrocortisone—psoriasis	0.00491	0.00711	CbGbCtD
Fluvoxamine—CYP3A4—Prednisone—psoriasis	0.0049	0.00708	CbGbCtD
Fluvoxamine—CYP2D6—Dexamethasone—psoriasis	0.00481	0.00695	CbGbCtD
Fluvoxamine—CYP3A4—Cyclosporine—psoriasis	0.00464	0.00671	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—psoriasis	0.0041	0.00593	CbGbCtD
Fluvoxamine—CYP3A4—Dexamethasone—psoriasis	0.00306	0.00442	CbGbCtD
Fluvoxamine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00164	0.0406	CbGpPWpGaD
Fluvoxamine—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.0016	0.0398	CbGpPWpGaD
Fluvoxamine—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00137	0.034	CbGpPWpGaD
Fluvoxamine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00124	0.0307	CbGpPWpGaD
Fluvoxamine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00114	0.0282	CbGpPWpGaD
Fluvoxamine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00113	0.028	CbGpPWpGaD
Fluvoxamine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00106	0.0263	CbGpPWpGaD
Fluvoxamine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00102	0.0252	CbGpPWpGaD
Fluvoxamine—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.000995	0.0247	CbGpPWpGaD
Fluvoxamine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000993	0.0246	CbGpPWpGaD
Fluvoxamine—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.000938	0.0232	CbGpPWpGaD
Fluvoxamine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000767	0.019	CbGpPWpGaD
Fluvoxamine—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.000759	1	CbGdCrCtD
Fluvoxamine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000706	0.0175	CbGpPWpGaD
Fluvoxamine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.0007	0.0173	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000601	0.0149	CbGpPWpGaD
Fluvoxamine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000598	0.0148	CbGpPWpGaD
Fluvoxamine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00057	0.0141	CbGpPWpGaD
Fluvoxamine—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000563	0.0139	CbGpPWpGaD
Fluvoxamine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000462	0.0115	CbGpPWpGaD
Fluvoxamine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000461	0.0114	CbGpPWpGaD
Fluvoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000422	0.0105	CbGpPWpGaD
Fluvoxamine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000416	0.0103	CbGpPWpGaD
Fluvoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000413	0.0102	CbGpPWpGaD
Fluvoxamine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000412	0.0102	CbGpPWpGaD
Fluvoxamine—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000408	0.0101	CbGpPWpGaD
Fluvoxamine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000407	0.0101	CbGpPWpGaD
Fluvoxamine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000389	0.00965	CbGpPWpGaD
Fluvoxamine—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000384	0.00952	CbGpPWpGaD
Fluvoxamine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000342	0.00847	CbGpPWpGaD
Fluvoxamine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000335	0.0083	CbGpPWpGaD
Fluvoxamine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000334	0.00828	CbGpPWpGaD
Fluvoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000319	0.0079	CbGpPWpGaD
Fluvoxamine—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000316	0.00782	CbGpPWpGaD
Fluvoxamine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000314	0.00779	CbGpPWpGaD
Fluvoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000293	0.00726	CbGpPWpGaD
Fluvoxamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000291	0.0072	CbGpPWpGaD
Fluvoxamine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000289	0.00717	CbGpPWpGaD
Fluvoxamine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000287	0.00711	CbGpPWpGaD
Fluvoxamine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000258	0.0064	CbGpPWpGaD
Fluvoxamine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000249	0.00616	CbGpPWpGaD
Fluvoxamine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000248	0.00615	CbGpPWpGaD
Fluvoxamine—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000246	0.00609	CbGpPWpGaD
Fluvoxamine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000245	0.00607	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000242	0.006	CbGpPWpGaD
Fluvoxamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000238	0.00589	CbGpPWpGaD
Fluvoxamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000236	0.00584	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00022	0.00544	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000218	0.00541	CbGpPWpGaD
Fluvoxamine—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000204	0.00505	CbGpPWpGaD
Fluvoxamine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000201	0.00499	CbGpPWpGaD
Fluvoxamine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000197	0.00488	CbGpPWpGaD
Fluvoxamine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000194	0.0048	CbGpPWpGaD
Fluvoxamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000192	0.00475	CbGpPWpGaD
Fluvoxamine—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000191	0.00473	CbGpPWpGaD
Fluvoxamine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00019	0.0047	CbGpPWpGaD
Fluvoxamine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000189	0.00469	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000187	0.00463	CbGpPWpGaD
Fluvoxamine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000182	0.0045	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000179	0.00444	CbGpPWpGaD
Fluvoxamine—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000178	0.00441	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000177	0.0044	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000175	0.00435	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000175	0.00434	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000173	0.0043	CbGpPWpGaD
Fluvoxamine—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000168	0.00416	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000165	0.0041	CbGpPWpGaD
Fluvoxamine—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000165	0.00409	CbGpPWpGaD
Fluvoxamine—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000163	0.00403	CbGpPWpGaD
Fluvoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000155	0.00385	CbGpPWpGaD
Fluvoxamine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000153	0.0038	CbGpPWpGaD
Fluvoxamine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000153	0.0038	CbGpPWpGaD
Fluvoxamine—SLC6A3—NRF2 pathway—TGFA—psoriasis	0.00015	0.00372	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000148	0.00366	CbGpPWpGaD
Fluvoxamine—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000147	0.00363	CbGpPWpGaD
Fluvoxamine—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000145	0.00359	CbGpPWpGaD
Fluvoxamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000143	0.00354	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000137	0.0034	CbGpPWpGaD
Fluvoxamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000136	0.00337	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000135	0.00335	CbGpPWpGaD
Fluvoxamine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000135	0.00335	CbGpPWpGaD
Fluvoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000133	0.00331	CbGpPWpGaD
Fluvoxamine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000133	0.0033	CbGpPWpGaD
Fluvoxamine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000132	0.00328	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000126	0.00313	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000125	0.0031	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000124	0.00308	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000123	0.00306	CbGpPWpGaD
Fluvoxamine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000122	0.00303	CbGpPWpGaD
Fluvoxamine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000122	0.00302	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000119	0.00295	CbGpPWpGaD
Fluvoxamine—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000117	0.0029	CbGpPWpGaD
Fluvoxamine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000115	0.00284	CbGpPWpGaD
Fluvoxamine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000114	0.00283	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000114	0.00282	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000113	0.0028	CbGpPWpGaD
Fluvoxamine—SLC6A3—Monoamine Transport—TNF—psoriasis	0.000112	0.00277	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000108	0.00269	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000107	0.00265	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000105	0.00261	CbGpPWpGaD
Fluvoxamine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000105	0.00261	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000104	0.00258	CbGpPWpGaD
Fluvoxamine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000104	0.00257	CbGpPWpGaD
Fluvoxamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.96e-05	0.00247	CbGpPWpGaD
Fluvoxamine—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	9.91e-05	0.00246	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL12B—psoriasis	9.68e-05	0.0024	CbGpPWpGaD
Fluvoxamine—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	9.67e-05	0.0024	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-E—psoriasis	9.45e-05	0.00234	CbGpPWpGaD
Fluvoxamine—CYP1A1—Oxidative Stress—NFKB1—psoriasis	9.41e-05	0.00233	CbGpPWpGaD
Fluvoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.3e-05	0.00231	CbGpPWpGaD
Fluvoxamine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	9.22e-05	0.00229	CbGpPWpGaD
Fluvoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.8e-05	0.00218	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.25e-05	0.00205	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.14e-05	0.00202	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.03e-05	0.00199	CbGpPWpGaD
Fluvoxamine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.95e-05	0.00197	CbGpPWpGaD
Fluvoxamine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.91e-05	0.00196	CbGpPWpGaD
Fluvoxamine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	7.9e-05	0.00196	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.82e-05	0.00194	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	7.29e-05	0.00181	CbGpPWpGaD
Fluvoxamine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.28e-05	0.0018	CbGpPWpGaD
Fluvoxamine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.12e-05	0.00176	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL10—psoriasis	7.08e-05	0.00175	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.94e-05	0.00172	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL4—psoriasis	6.89e-05	0.00171	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	6.79e-05	0.00168	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.73e-05	0.00167	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.73e-05	0.00167	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.69e-05	0.00166	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	6.35e-05	0.00157	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.27e-05	0.00155	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.24e-05	0.00155	CbGpPWpGaD
Fluvoxamine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.17e-05	0.00153	CbGpPWpGaD
Fluvoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.14e-05	0.00152	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.07e-05	0.0015	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.93e-05	0.00147	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.7e-05	0.00141	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	5.51e-05	0.00137	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.31e-05	0.00132	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.2e-05	0.00129	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.2e-05	0.00129	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.12e-05	0.00127	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	5.04e-05	0.00125	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—NDUFA5—psoriasis	4.94e-05	0.00122	CbGpPWpGaD
Fluvoxamine—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	4.87e-05	0.00121	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.82e-05	0.00119	CbGpPWpGaD
Fluvoxamine—Vomiting—Mycophenolic acid—psoriasis	4.82e-05	0.00018	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	4.8e-05	0.00119	CbGpPWpGaD
Fluvoxamine—Discomfort—Betamethasone—psoriasis	4.8e-05	0.000179	CcSEcCtD
Fluvoxamine—Discomfort—Dexamethasone—psoriasis	4.8e-05	0.000179	CcSEcCtD
Fluvoxamine—Dyspepsia—Hydrocortisone—psoriasis	4.79e-05	0.000179	CcSEcCtD
Fluvoxamine—Haemoglobin—Methotrexate—psoriasis	4.79e-05	0.000179	CcSEcCtD
Fluvoxamine—Rash—Mycophenolic acid—psoriasis	4.78e-05	0.000179	CcSEcCtD
Fluvoxamine—Dermatitis—Mycophenolic acid—psoriasis	4.77e-05	0.000178	CcSEcCtD
Fluvoxamine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	4.77e-05	0.00118	CbGpPWpGaD
Fluvoxamine—Pain—Prednisolone—psoriasis	4.77e-05	0.000178	CcSEcCtD
Fluvoxamine—Haemorrhage—Methotrexate—psoriasis	4.77e-05	0.000178	CcSEcCtD
Fluvoxamine—Hepatitis—Methotrexate—psoriasis	4.77e-05	0.000178	CcSEcCtD
Fluvoxamine—Urticaria—Mycophenolate mofetil—psoriasis	4.75e-05	0.000178	CcSEcCtD
Fluvoxamine—Headache—Mycophenolic acid—psoriasis	4.75e-05	0.000177	CcSEcCtD
Fluvoxamine—Decreased appetite—Hydrocortisone—psoriasis	4.73e-05	0.000177	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—psoriasis	4.73e-05	0.000177	CcSEcCtD
Fluvoxamine—Abdominal pain—Mycophenolate mofetil—psoriasis	4.73e-05	0.000177	CcSEcCtD
Fluvoxamine—Body temperature increased—Mycophenolate mofetil—psoriasis	4.73e-05	0.000177	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Methotrexate—psoriasis	4.71e-05	0.000176	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.7e-05	0.000176	CcSEcCtD
Fluvoxamine—Fatigue—Hydrocortisone—psoriasis	4.7e-05	0.000176	CcSEcCtD
Fluvoxamine—Vision blurred—Prednisone—psoriasis	4.68e-05	0.000175	CcSEcCtD
Fluvoxamine—Urethral disorder—Methotrexate—psoriasis	4.67e-05	0.000175	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.67e-05	0.000175	CcSEcCtD
Fluvoxamine—Pain—Hydrocortisone—psoriasis	4.66e-05	0.000174	CcSEcCtD
Fluvoxamine—Oedema—Dexamethasone—psoriasis	4.65e-05	0.000174	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Dexamethasone—psoriasis	4.65e-05	0.000174	CcSEcCtD
Fluvoxamine—Oedema—Betamethasone—psoriasis	4.65e-05	0.000174	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Betamethasone—psoriasis	4.65e-05	0.000174	CcSEcCtD
Fluvoxamine—Insomnia—Triamcinolone—psoriasis	4.64e-05	0.000173	CcSEcCtD
Fluvoxamine—Infection—Betamethasone—psoriasis	4.62e-05	0.000173	CcSEcCtD
Fluvoxamine—Infection—Dexamethasone—psoriasis	4.62e-05	0.000173	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Prednisone—psoriasis	4.61e-05	0.000172	CcSEcCtD
Fluvoxamine—Paraesthesia—Triamcinolone—psoriasis	4.6e-05	0.000172	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisolone—psoriasis	4.6e-05	0.000172	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—psoriasis	4.59e-05	0.000172	CcSEcCtD
Fluvoxamine—Anaemia—Prednisone—psoriasis	4.59e-05	0.000172	CcSEcCtD
Fluvoxamine—Shock—Dexamethasone—psoriasis	4.58e-05	0.000171	CcSEcCtD
Fluvoxamine—Shock—Betamethasone—psoriasis	4.58e-05	0.000171	CcSEcCtD
Fluvoxamine—Dyspnoea—Triamcinolone—psoriasis	4.57e-05	0.000171	CcSEcCtD
Fluvoxamine—Nervous system disorder—Dexamethasone—psoriasis	4.56e-05	0.000171	CcSEcCtD
Fluvoxamine—Nervous system disorder—Betamethasone—psoriasis	4.56e-05	0.000171	CcSEcCtD
Fluvoxamine—Agitation—Prednisone—psoriasis	4.56e-05	0.000171	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Betamethasone—psoriasis	4.56e-05	0.00017	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Dexamethasone—psoriasis	4.56e-05	0.00017	CcSEcCtD
Fluvoxamine—Tachycardia—Betamethasone—psoriasis	4.54e-05	0.00017	CcSEcCtD
Fluvoxamine—Tachycardia—Dexamethasone—psoriasis	4.54e-05	0.00017	CcSEcCtD
Fluvoxamine—Angioedema—Prednisone—psoriasis	4.54e-05	0.00017	CcSEcCtD
Fluvoxamine—Hypersensitivity—Cyclosporine—psoriasis	4.51e-05	0.000169	CcSEcCtD
Fluvoxamine—Dyspepsia—Triamcinolone—psoriasis	4.51e-05	0.000169	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—psoriasis	4.51e-05	0.000168	CcSEcCtD
Fluvoxamine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	4.5e-05	0.00112	CbGpPWpGaD
Fluvoxamine—Nausea—Mycophenolic acid—psoriasis	4.5e-05	0.000168	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Betamethasone—psoriasis	4.5e-05	0.000168	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Dexamethasone—psoriasis	4.5e-05	0.000168	CcSEcCtD
Fluvoxamine—Feeling abnormal—Hydrocortisone—psoriasis	4.49e-05	0.000168	CcSEcCtD
Fluvoxamine—Malaise—Prednisone—psoriasis	4.48e-05	0.000167	CcSEcCtD
Fluvoxamine—Vertigo—Prednisone—psoriasis	4.46e-05	0.000167	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—psoriasis	4.45e-05	0.000167	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Hydrocortisone—psoriasis	4.45e-05	0.000166	CcSEcCtD
Fluvoxamine—Syncope—Prednisone—psoriasis	4.45e-05	0.000166	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—psoriasis	4.44e-05	0.000166	CcSEcCtD
Fluvoxamine—Anorexia—Betamethasone—psoriasis	4.44e-05	0.000166	CcSEcCtD
Fluvoxamine—Anorexia—Dexamethasone—psoriasis	4.44e-05	0.000166	CcSEcCtD
Fluvoxamine—Urticaria—Prednisolone—psoriasis	4.43e-05	0.000166	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.43e-05	0.0011	CbGpPWpGaD
Fluvoxamine—Cardiac disorder—Methotrexate—psoriasis	4.42e-05	0.000165	CcSEcCtD
Fluvoxamine—Fatigue—Triamcinolone—psoriasis	4.42e-05	0.000165	CcSEcCtD
Fluvoxamine—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.4e-05	0.000165	CcSEcCtD
Fluvoxamine—Asthenia—Cyclosporine—psoriasis	4.4e-05	0.000164	CcSEcCtD
Fluvoxamine—Pain—Triamcinolone—psoriasis	4.39e-05	0.000164	CcSEcCtD
Fluvoxamine—Loss of consciousness—Prednisone—psoriasis	4.36e-05	0.000163	CcSEcCtD
Fluvoxamine—Hypotension—Dexamethasone—psoriasis	4.35e-05	0.000163	CcSEcCtD
Fluvoxamine—Hypotension—Betamethasone—psoriasis	4.35e-05	0.000163	CcSEcCtD
Fluvoxamine—Pruritus—Cyclosporine—psoriasis	4.34e-05	0.000162	CcSEcCtD
Fluvoxamine—Urticaria—Hydrocortisone—psoriasis	4.33e-05	0.000162	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—psoriasis	4.32e-05	0.000162	CcSEcCtD
Fluvoxamine—Body temperature increased—Hydrocortisone—psoriasis	4.31e-05	0.000161	CcSEcCtD
Fluvoxamine—Abdominal pain—Hydrocortisone—psoriasis	4.31e-05	0.000161	CcSEcCtD
Fluvoxamine—Convulsion—Prednisone—psoriasis	4.3e-05	0.000161	CcSEcCtD
Fluvoxamine—Asthenia—Mycophenolate mofetil—psoriasis	4.29e-05	0.00016	CcSEcCtD
Fluvoxamine—Hypertension—Prednisone—psoriasis	4.29e-05	0.00016	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—psoriasis	4.28e-05	0.00016	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.26e-05	0.00106	CbGpPWpGaD
Fluvoxamine—Musculoskeletal discomfort—Betamethasone—psoriasis	4.24e-05	0.000158	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.24e-05	0.000158	CcSEcCtD
Fluvoxamine—Pruritus—Mycophenolate mofetil—psoriasis	4.23e-05	0.000158	CcSEcCtD
Fluvoxamine—Arthralgia—Prednisone—psoriasis	4.23e-05	0.000158	CcSEcCtD
Fluvoxamine—Myalgia—Prednisone—psoriasis	4.23e-05	0.000158	CcSEcCtD
Fluvoxamine—Feeling abnormal—Triamcinolone—psoriasis	4.23e-05	0.000158	CcSEcCtD
Fluvoxamine—Anxiety—Prednisone—psoriasis	4.21e-05	0.000157	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—psoriasis	4.21e-05	0.000157	CcSEcCtD
Fluvoxamine—Insomnia—Betamethasone—psoriasis	4.21e-05	0.000157	CcSEcCtD
Fluvoxamine—Insomnia—Dexamethasone—psoriasis	4.21e-05	0.000157	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—CYP2S1—psoriasis	4.2e-05	0.00104	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Cyclosporine—psoriasis	4.19e-05	0.000157	CcSEcCtD
Fluvoxamine—Paraesthesia—Dexamethasone—psoriasis	4.18e-05	0.000156	CcSEcCtD
Fluvoxamine—Paraesthesia—Betamethasone—psoriasis	4.18e-05	0.000156	CcSEcCtD
Fluvoxamine—Discomfort—Prednisone—psoriasis	4.18e-05	0.000156	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—psoriasis	4.18e-05	0.000156	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—IFNG—psoriasis	4.16e-05	0.00103	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.16e-05	0.00103	CbGpPWpGaD
Fluvoxamine—Malnutrition—Methotrexate—psoriasis	4.15e-05	0.000155	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	4.13e-05	0.00102	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Prednisolone—psoriasis	4.11e-05	0.000154	CcSEcCtD
Fluvoxamine—Dyspepsia—Dexamethasone—psoriasis	4.1e-05	0.000153	CcSEcCtD
Fluvoxamine—Dyspepsia—Betamethasone—psoriasis	4.1e-05	0.000153	CcSEcCtD
Fluvoxamine—Diarrhoea—Mycophenolate mofetil—psoriasis	4.09e-05	0.000153	CcSEcCtD
Fluvoxamine—Urticaria—Triamcinolone—psoriasis	4.07e-05	0.000152	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—psoriasis	4.06e-05	0.000152	CcSEcCtD
Fluvoxamine—Body temperature increased—Triamcinolone—psoriasis	4.05e-05	0.000152	CcSEcCtD
Fluvoxamine—Dizziness—Cyclosporine—psoriasis	4.05e-05	0.000151	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Prednisone—psoriasis	4.05e-05	0.000151	CcSEcCtD
Fluvoxamine—Oedema—Prednisone—psoriasis	4.05e-05	0.000151	CcSEcCtD
Fluvoxamine—Decreased appetite—Dexamethasone—psoriasis	4.04e-05	0.000151	CcSEcCtD
Fluvoxamine—Decreased appetite—Betamethasone—psoriasis	4.04e-05	0.000151	CcSEcCtD
Fluvoxamine—Infection—Prednisone—psoriasis	4.03e-05	0.00015	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Dexamethasone—psoriasis	4.02e-05	0.00015	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Betamethasone—psoriasis	4.02e-05	0.00015	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—psoriasis	4.01e-05	0.00015	CcSEcCtD
Fluvoxamine—Hypersensitivity—Hydrocortisone—psoriasis	4.01e-05	0.00015	CcSEcCtD
Fluvoxamine—Fatigue—Dexamethasone—psoriasis	4.01e-05	0.00015	CcSEcCtD
Fluvoxamine—Fatigue—Betamethasone—psoriasis	4.01e-05	0.00015	CcSEcCtD
Fluvoxamine—Shock—Prednisone—psoriasis	3.99e-05	0.000149	CcSEcCtD
Fluvoxamine—Pain—Betamethasone—psoriasis	3.98e-05	0.000149	CcSEcCtD
Fluvoxamine—Pain—Dexamethasone—psoriasis	3.98e-05	0.000149	CcSEcCtD
Fluvoxamine—Nervous system disorder—Prednisone—psoriasis	3.97e-05	0.000149	CcSEcCtD
Fluvoxamine—Tachycardia—Prednisone—psoriasis	3.95e-05	0.000148	CcSEcCtD
Fluvoxamine—Dizziness—Mycophenolate mofetil—psoriasis	3.95e-05	0.000148	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Prednisone—psoriasis	3.92e-05	0.000146	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—psoriasis	3.91e-05	0.000146	CcSEcCtD
Fluvoxamine—Asthenia—Hydrocortisone—psoriasis	3.91e-05	0.000146	CcSEcCtD
Fluvoxamine—Vomiting—Cyclosporine—psoriasis	3.9e-05	0.000146	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.87e-05	0.000959	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.87e-05	0.000959	CbGpPWpGaD
Fluvoxamine—Rash—Cyclosporine—psoriasis	3.86e-05	0.000144	CcSEcCtD
Fluvoxamine—Anorexia—Prednisone—psoriasis	3.86e-05	0.000144	CcSEcCtD
Fluvoxamine—Dermatitis—Cyclosporine—psoriasis	3.86e-05	0.000144	CcSEcCtD
Fluvoxamine—Pruritus—Hydrocortisone—psoriasis	3.85e-05	0.000144	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—psoriasis	3.85e-05	0.000144	CcSEcCtD
Fluvoxamine—Headache—Cyclosporine—psoriasis	3.84e-05	0.000143	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—psoriasis	3.84e-05	0.000143	CcSEcCtD
Fluvoxamine—Feeling abnormal—Dexamethasone—psoriasis	3.83e-05	0.000143	CcSEcCtD
Fluvoxamine—Feeling abnormal—Betamethasone—psoriasis	3.83e-05	0.000143	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Betamethasone—psoriasis	3.8e-05	0.000142	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Dexamethasone—psoriasis	3.8e-05	0.000142	CcSEcCtD
Fluvoxamine—Vomiting—Mycophenolate mofetil—psoriasis	3.8e-05	0.000142	CcSEcCtD
Fluvoxamine—Hypersensitivity—Triamcinolone—psoriasis	3.78e-05	0.000141	CcSEcCtD
Fluvoxamine—Rash—Mycophenolate mofetil—psoriasis	3.77e-05	0.000141	CcSEcCtD
Fluvoxamine—Dermatitis—Mycophenolate mofetil—psoriasis	3.77e-05	0.000141	CcSEcCtD
Fluvoxamine—Headache—Mycophenolate mofetil—psoriasis	3.74e-05	0.00014	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—psoriasis	3.74e-05	0.00014	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—psoriasis	3.73e-05	0.000139	CcSEcCtD
Fluvoxamine—Diarrhoea—Hydrocortisone—psoriasis	3.73e-05	0.000139	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—psoriasis	3.71e-05	0.000139	CcSEcCtD
Fluvoxamine—Urticaria—Dexamethasone—psoriasis	3.7e-05	0.000138	CcSEcCtD
Fluvoxamine—Urticaria—Betamethasone—psoriasis	3.7e-05	0.000138	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Prednisone—psoriasis	3.69e-05	0.000138	CcSEcCtD
Fluvoxamine—Dizziness—Prednisolone—psoriasis	3.69e-05	0.000138	CcSEcCtD
Fluvoxamine—Asthenia—Triamcinolone—psoriasis	3.68e-05	0.000138	CcSEcCtD
Fluvoxamine—Body temperature increased—Dexamethasone—psoriasis	3.68e-05	0.000137	CcSEcCtD
Fluvoxamine—Abdominal pain—Dexamethasone—psoriasis	3.68e-05	0.000137	CcSEcCtD
Fluvoxamine—Body temperature increased—Betamethasone—psoriasis	3.68e-05	0.000137	CcSEcCtD
Fluvoxamine—Abdominal pain—Betamethasone—psoriasis	3.68e-05	0.000137	CcSEcCtD
Fluvoxamine—Insomnia—Prednisone—psoriasis	3.67e-05	0.000137	CcSEcCtD
Fluvoxamine—CYP2B6—Metabolism—NDUFA5—psoriasis	3.65e-05	0.000905	CbGpPWpGaD
Fluvoxamine—Nausea—Cyclosporine—psoriasis	3.64e-05	0.000136	CcSEcCtD
Fluvoxamine—Paraesthesia—Prednisone—psoriasis	3.64e-05	0.000136	CcSEcCtD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.63e-05	0.0009	CbGpPWpGaD
Fluvoxamine—Pruritus—Triamcinolone—psoriasis	3.63e-05	0.000136	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—psoriasis	3.62e-05	0.000135	CcSEcCtD
Fluvoxamine—Dizziness—Hydrocortisone—psoriasis	3.6e-05	0.000135	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—psoriasis	3.6e-05	0.000134	CcSEcCtD
Fluvoxamine—CYP2E1—Metabolism—NDUFA5—psoriasis	3.58e-05	0.000887	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NDUFA5—psoriasis	3.57e-05	0.000885	CbGpPWpGaD
Fluvoxamine—Dyspepsia—Prednisone—psoriasis	3.57e-05	0.000133	CcSEcCtD
Fluvoxamine—Nausea—Mycophenolate mofetil—psoriasis	3.55e-05	0.000133	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—psoriasis	3.53e-05	0.000132	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—psoriasis	3.53e-05	0.000132	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—psoriasis	3.53e-05	0.000132	CcSEcCtD
Fluvoxamine—Decreased appetite—Prednisone—psoriasis	3.52e-05	0.000132	CcSEcCtD
Fluvoxamine—Rash—Prednisolone—psoriasis	3.52e-05	0.000131	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisolone—psoriasis	3.51e-05	0.000131	CcSEcCtD
Fluvoxamine—Fatigue—Prednisone—psoriasis	3.49e-05	0.000131	CcSEcCtD
Fluvoxamine—Headache—Prednisolone—psoriasis	3.49e-05	0.000131	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—psoriasis	3.49e-05	0.00013	CcSEcCtD
Fluvoxamine—Constipation—Prednisone—psoriasis	3.47e-05	0.00013	CcSEcCtD
Fluvoxamine—Vomiting—Hydrocortisone—psoriasis	3.46e-05	0.000129	CcSEcCtD
Fluvoxamine—Rash—Hydrocortisone—psoriasis	3.43e-05	0.000128	CcSEcCtD
Fluvoxamine—Dermatitis—Hydrocortisone—psoriasis	3.43e-05	0.000128	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—psoriasis	3.41e-05	0.000128	CcSEcCtD
Fluvoxamine—Headache—Hydrocortisone—psoriasis	3.41e-05	0.000128	CcSEcCtD
Fluvoxamine—Dizziness—Triamcinolone—psoriasis	3.39e-05	0.000127	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—psoriasis	3.39e-05	0.000127	CcSEcCtD
Fluvoxamine—CYP1A1—Metabolism—NDUFA5—psoriasis	3.37e-05	0.000836	CbGpPWpGaD
Fluvoxamine—Infection—Methotrexate—psoriasis	3.36e-05	0.000126	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisone—psoriasis	3.34e-05	0.000125	CcSEcCtD
Fluvoxamine—Asthenia—Dexamethasone—psoriasis	3.34e-05	0.000125	CcSEcCtD
Fluvoxamine—Asthenia—Betamethasone—psoriasis	3.34e-05	0.000125	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	3.33e-05	0.000826	CbGpPWpGaD
Fluvoxamine—Nervous system disorder—Methotrexate—psoriasis	3.32e-05	0.000124	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—psoriasis	3.32e-05	0.000124	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.32e-05	0.000822	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.32e-05	0.000822	CbGpPWpGaD
Fluvoxamine—Gastrointestinal pain—Prednisone—psoriasis	3.31e-05	0.000124	CcSEcCtD
Fluvoxamine—Nausea—Prednisolone—psoriasis	3.31e-05	0.000124	CcSEcCtD
Fluvoxamine—Pruritus—Dexamethasone—psoriasis	3.29e-05	0.000123	CcSEcCtD
Fluvoxamine—Pruritus—Betamethasone—psoriasis	3.29e-05	0.000123	CcSEcCtD
Fluvoxamine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.29e-05	0.000815	CbGpPWpGaD
Fluvoxamine—Hyperhidrosis—Methotrexate—psoriasis	3.27e-05	0.000122	CcSEcCtD
Fluvoxamine—Vomiting—Triamcinolone—psoriasis	3.26e-05	0.000122	CcSEcCtD
Fluvoxamine—Nausea—Hydrocortisone—psoriasis	3.23e-05	0.000121	CcSEcCtD
Fluvoxamine—Rash—Triamcinolone—psoriasis	3.23e-05	0.000121	CcSEcCtD
Fluvoxamine—Dermatitis—Triamcinolone—psoriasis	3.23e-05	0.000121	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—psoriasis	3.23e-05	0.000121	CcSEcCtD
Fluvoxamine—Urticaria—Prednisone—psoriasis	3.22e-05	0.00012	CcSEcCtD
Fluvoxamine—Headache—Triamcinolone—psoriasis	3.21e-05	0.00012	CcSEcCtD
Fluvoxamine—Abdominal pain—Prednisone—psoriasis	3.2e-05	0.00012	CcSEcCtD
Fluvoxamine—Body temperature increased—Prednisone—psoriasis	3.2e-05	0.00012	CcSEcCtD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.19e-05	0.00079	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Betamethasone—psoriasis	3.18e-05	0.000119	CcSEcCtD
Fluvoxamine—Diarrhoea—Dexamethasone—psoriasis	3.18e-05	0.000119	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—psoriasis	3.16e-05	0.000118	CcSEcCtD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.14e-05	0.000779	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.14e-05	0.000779	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP2S1—psoriasis	3.11e-05	0.00077	CbGpPWpGaD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—psoriasis	3.09e-05	0.000115	CcSEcCtD
Fluvoxamine—Dizziness—Betamethasone—psoriasis	3.08e-05	0.000115	CcSEcCtD
Fluvoxamine—Dizziness—Dexamethasone—psoriasis	3.08e-05	0.000115	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—psoriasis	3.06e-05	0.000114	CcSEcCtD
Fluvoxamine—Nausea—Triamcinolone—psoriasis	3.05e-05	0.000114	CcSEcCtD
Fluvoxamine—CYP2E1—Metabolism—CYP2S1—psoriasis	3.04e-05	0.000754	CbGpPWpGaD
Fluvoxamine—Paraesthesia—Methotrexate—psoriasis	3.04e-05	0.000114	CcSEcCtD
Fluvoxamine—CYP3A5—Metabolism—CYP2S1—psoriasis	3.04e-05	0.000752	CbGpPWpGaD
Fluvoxamine—Dyspnoea—Methotrexate—psoriasis	3.02e-05	0.000113	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—psoriasis	3.01e-05	0.000113	CcSEcCtD
Fluvoxamine—Hypersensitivity—Prednisone—psoriasis	2.99e-05	0.000112	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—psoriasis	2.98e-05	0.000111	CcSEcCtD
Fluvoxamine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	2.97e-05	0.000737	CbGpPWpGaD
Fluvoxamine—Vomiting—Betamethasone—psoriasis	2.96e-05	0.000111	CcSEcCtD
Fluvoxamine—Vomiting—Dexamethasone—psoriasis	2.96e-05	0.000111	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—psoriasis	2.94e-05	0.00011	CcSEcCtD
Fluvoxamine—Rash—Betamethasone—psoriasis	2.93e-05	0.00011	CcSEcCtD
Fluvoxamine—Rash—Dexamethasone—psoriasis	2.93e-05	0.00011	CcSEcCtD
Fluvoxamine—Dermatitis—Betamethasone—psoriasis	2.93e-05	0.00011	CcSEcCtD
Fluvoxamine—Dermatitis—Dexamethasone—psoriasis	2.93e-05	0.00011	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—psoriasis	2.92e-05	0.000109	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—psoriasis	2.92e-05	0.000109	CcSEcCtD
Fluvoxamine—Headache—Dexamethasone—psoriasis	2.91e-05	0.000109	CcSEcCtD
Fluvoxamine—Headache—Betamethasone—psoriasis	2.91e-05	0.000109	CcSEcCtD
Fluvoxamine—Asthenia—Prednisone—psoriasis	2.91e-05	0.000109	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—psoriasis	2.9e-05	0.000108	CcSEcCtD
Fluvoxamine—CYP1A1—Metabolism—CYP2S1—psoriasis	2.87e-05	0.000711	CbGpPWpGaD
Fluvoxamine—Pruritus—Prednisone—psoriasis	2.87e-05	0.000107	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—psoriasis	2.79e-05	0.000104	CcSEcCtD
Fluvoxamine—Diarrhoea—Prednisone—psoriasis	2.77e-05	0.000104	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—psoriasis	2.77e-05	0.000104	CcSEcCtD
Fluvoxamine—Nausea—Betamethasone—psoriasis	2.76e-05	0.000103	CcSEcCtD
Fluvoxamine—Nausea—Dexamethasone—psoriasis	2.76e-05	0.000103	CcSEcCtD
Fluvoxamine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.76e-05	0.000684	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	2.72e-05	0.000674	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—TNF—psoriasis	2.69e-05	0.000668	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NDUFA5—psoriasis	2.69e-05	0.000668	CbGpPWpGaD
Fluvoxamine—Urticaria—Methotrexate—psoriasis	2.69e-05	0.000101	CcSEcCtD
Fluvoxamine—Dizziness—Prednisone—psoriasis	2.68e-05	0.0001	CcSEcCtD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.68e-05	0.000664	CbGpPWpGaD
Fluvoxamine—Abdominal pain—Methotrexate—psoriasis	2.68e-05	0.0001	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—psoriasis	2.68e-05	0.0001	CcSEcCtD
Fluvoxamine—Vomiting—Prednisone—psoriasis	2.58e-05	9.63e-05	CcSEcCtD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.57e-05	0.000638	CbGpPWpGaD
Fluvoxamine—Rash—Prednisone—psoriasis	2.55e-05	9.55e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisone—psoriasis	2.55e-05	9.54e-05	CcSEcCtD
Fluvoxamine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.54e-05	0.000629	CbGpPWpGaD
Fluvoxamine—Headache—Prednisone—psoriasis	2.54e-05	9.49e-05	CcSEcCtD
Fluvoxamine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.52e-05	0.000624	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.5e-05	0.00062	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Methotrexate—psoriasis	2.5e-05	9.33e-05	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—psoriasis	2.43e-05	9.08e-05	CcSEcCtD
Fluvoxamine—Nausea—Prednisone—psoriasis	2.41e-05	9e-05	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—psoriasis	2.4e-05	8.96e-05	CcSEcCtD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.39e-05	0.000592	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.35e-05	0.000582	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.35e-05	0.000582	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Methotrexate—psoriasis	2.32e-05	8.66e-05	CcSEcCtD
Fluvoxamine—ABCB1—Metabolism—CYP2S1—psoriasis	2.29e-05	0.000568	CbGpPWpGaD
Fluvoxamine—Dizziness—Methotrexate—psoriasis	2.24e-05	8.37e-05	CcSEcCtD
Fluvoxamine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.16e-05	0.000535	CbGpPWpGaD
Fluvoxamine—Vomiting—Methotrexate—psoriasis	2.15e-05	8.05e-05	CcSEcCtD
Fluvoxamine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.15e-05	0.000533	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.14e-05	0.00053	CbGpPWpGaD
Fluvoxamine—Rash—Methotrexate—psoriasis	2.14e-05	7.98e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—psoriasis	2.13e-05	7.97e-05	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—psoriasis	2.12e-05	7.93e-05	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—CARM1—psoriasis	2.05e-05	0.000508	CbGpPWpGaD
Fluvoxamine—Nausea—Methotrexate—psoriasis	2.01e-05	7.52e-05	CcSEcCtD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.01e-05	0.000497	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.83e-05	0.000453	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.78e-05	0.00044	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.71e-05	0.000424	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.66e-05	0.000411	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.55e-05	0.000385	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CARM1—psoriasis	1.52e-05	0.000376	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.5e-05	0.000372	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CARM1—psoriasis	1.49e-05	0.000368	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CARM1—psoriasis	1.48e-05	0.000367	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.41e-05	0.00035	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CARM1—psoriasis	1.4e-05	0.000347	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.33e-05	0.00033	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.31e-05	0.000324	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CAT—psoriasis	1.26e-05	0.000313	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.000305	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.17e-05	0.000291	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CARM1—psoriasis	1.15e-05	0.000284	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.12e-05	0.000278	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CARM1—psoriasis	1.12e-05	0.000277	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	0.000265	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CARM1—psoriasis	1.05e-05	0.000261	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CARM1—psoriasis	1.05e-05	0.000259	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—APOE—psoriasis	9.8e-06	0.000243	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.77e-06	0.000242	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.58e-06	0.000237	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CAT—psoriasis	9.33e-06	0.000231	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CAT—psoriasis	9.14e-06	0.000226	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CAT—psoriasis	9.12e-06	0.000226	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CARM1—psoriasis	8.93e-06	0.000221	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CAT—psoriasis	8.61e-06	0.000213	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PPARG—psoriasis	8.54e-06	0.000212	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.35e-06	0.000207	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—APOE—psoriasis	7.25e-06	0.00018	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—APOE—psoriasis	7.1e-06	0.000176	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—APOE—psoriasis	7.08e-06	0.000176	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CAT—psoriasis	7.05e-06	0.000175	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CARM1—psoriasis	6.89e-06	0.000171	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CAT—psoriasis	6.88e-06	0.000171	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—APOE—psoriasis	6.69e-06	0.000166	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CAT—psoriasis	6.48e-06	0.000161	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CAT—psoriasis	6.43e-06	0.000159	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PPARG—psoriasis	6.31e-06	0.000156	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PPARG—psoriasis	6.18e-06	0.000153	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PPARG—psoriasis	6.17e-06	0.000153	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PPARG—psoriasis	5.83e-06	0.000144	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CAT—psoriasis	5.49e-06	0.000136	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—APOE—psoriasis	5.48e-06	0.000136	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—APOE—psoriasis	5.35e-06	0.000132	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—APOE—psoriasis	5.04e-06	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—APOE—psoriasis	4.99e-06	0.000124	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PPARG—psoriasis	4.77e-06	0.000118	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PPARG—psoriasis	4.66e-06	0.000115	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PPARG—psoriasis	4.39e-06	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PPARG—psoriasis	4.35e-06	0.000108	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—APOE—psoriasis	4.27e-06	0.000106	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CAT—psoriasis	4.24e-06	0.000105	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PPARG—psoriasis	3.72e-06	9.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—APOE—psoriasis	3.29e-06	8.16e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PPARG—psoriasis	2.87e-06	7.11e-05	CbGpPWpGaD
